

**EFFECTING CLINICAL STARTING MATERIAL QUALITY AND THE IMPACT TO DOWNSTREAM  
PROCESSING**

Dominic Clark, Global Head of Cell Therapy, HemaCare Corporation, USA  
DClarke@hemacare.com